Cerebral to pay nearly $3.7M over controlled substance prescribing practices

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Evotec SE reports results for the first half-year 2023 and provides corporate updates – Biotech Investments

EQS-News: Evotec SE / Key word(s): Half Year Report Evotec SE reports results for the first half-year 2023 and provides corporate updates 29.08.2023 / 07:00

August 30, 2023

Opinion | Spinal Surgery Redux: Advancing Our Approach to Back Pain

David Nash is the Founding Dean Emeritus and Dr. Raymond C. and Doris N. Grandon Professor of Health Policy at the Jefferson College of Population

October 31, 2023

Ikena inks small cash grab in all-stock deal for Pionyr to take cancer drug on Hippo pathway

Ikena Oncology said it added about $43 million to its runway after making an all-stock acquisition of the private startup Pionyr Immunotherapeutics, a clinical-stage company

August 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.